Clinical characteristics among 252 patients with ALKneg ALCL, AITL, TCL U, and EATL up to age 70 treated with CHOP/CHOEP
| . | Auto-SCT ITT (n = 128) . | Non–auto-SCT (n = 124) . | P . | CHOEP (n = 107) . | CHOP (n = 145) . | P . |
|---|---|---|---|---|---|---|
| Median age (range), y | 57 (24-68) | 65 (18-70) | <.001 | 52 (24-69) | 65 (18-70) | <.001 |
| Male | 87 (70) | 87 (68) | .707 | 72 (67) | 102 (70) | .604 |
| B symptoms | 83 (67) | 79 (62) | .536 | 72 (67) | 90 (62) | .414 |
| Ann Arbor I | 6 (5) | 24 (19) | 10 (9) | 20 (14) | ||
| II | 35 (28) | 18 (14) | 26 (24) | 27 (19) | ||
| III | 30 (24) | 28 (22) | .999* | 22 (21) | 36 (25) | .867* |
| IV | 53 (43) | 57 (45) | 49 (46) | 61 (42) | ||
| BM | 22 (18) | 29 (23) | .332 | 20 (19) | 31 (21) | .600 |
| Extranodal involvement >1 | 19 (15) | 18 (14) | .778 | 17 (16) | 20 (14) | .642 |
| WHO PS >0 | 71 (57) | 82 (64) | .176 | 63 (59) | 90 (62) | .574 |
| Bulky disease (>10 cm) | 9 (7) | 14 (11) | .292 | 7 (7) | 16 (11) | .223 |
| LDH > ULN | 83 (69) | 74 (60) | .233 | 67 (64) | 90 (64) | .797 |
| IPI 0-1 | 43 (35) | 28 (22) | .024 | 39 (37) | 32 (23) | .012 |
| IPI 2-3 | 62 (50) | 71 (56) | .385 | 57 (53) | 76 (54) | .893 |
| IPI 4-5 | 16 (13) | 23 (18) | .266 | 7 (7) | 32 (23) | .001 |
| CHOP | 42 (34) | 103 (80) | <.001 | — | — | — |
| CHOEP | 82 (66) | 25 (20) | — | — | — | — |
| PTCL NOS | 44 (34) | 65 (52) | — | 41 (38) | 68 (47) | — |
| ALKneg ALCL | 31 (24) | 21 (17) | — | 27 (25) | 25 (17) | — |
| AITL | 27 (21) | 20 (16) | — | 18 (17) | 29 (20) | — |
| EATL | 20 (16) | 14 (11) | — | 17 (16) | 17 (12) | — |
| TCL U | 2 (2) | 8 (6) | — | 4 (4) | 6 (4) | — |
| 5-y OS (%) | 48 | 26 | — | 47 | 30 | — |
| 5-y PFS (%) | 41 | 20 | — | 40 | 23 | — |
| . | Auto-SCT ITT (n = 128) . | Non–auto-SCT (n = 124) . | P . | CHOEP (n = 107) . | CHOP (n = 145) . | P . |
|---|---|---|---|---|---|---|
| Median age (range), y | 57 (24-68) | 65 (18-70) | <.001 | 52 (24-69) | 65 (18-70) | <.001 |
| Male | 87 (70) | 87 (68) | .707 | 72 (67) | 102 (70) | .604 |
| B symptoms | 83 (67) | 79 (62) | .536 | 72 (67) | 90 (62) | .414 |
| Ann Arbor I | 6 (5) | 24 (19) | 10 (9) | 20 (14) | ||
| II | 35 (28) | 18 (14) | 26 (24) | 27 (19) | ||
| III | 30 (24) | 28 (22) | .999* | 22 (21) | 36 (25) | .867* |
| IV | 53 (43) | 57 (45) | 49 (46) | 61 (42) | ||
| BM | 22 (18) | 29 (23) | .332 | 20 (19) | 31 (21) | .600 |
| Extranodal involvement >1 | 19 (15) | 18 (14) | .778 | 17 (16) | 20 (14) | .642 |
| WHO PS >0 | 71 (57) | 82 (64) | .176 | 63 (59) | 90 (62) | .574 |
| Bulky disease (>10 cm) | 9 (7) | 14 (11) | .292 | 7 (7) | 16 (11) | .223 |
| LDH > ULN | 83 (69) | 74 (60) | .233 | 67 (64) | 90 (64) | .797 |
| IPI 0-1 | 43 (35) | 28 (22) | .024 | 39 (37) | 32 (23) | .012 |
| IPI 2-3 | 62 (50) | 71 (56) | .385 | 57 (53) | 76 (54) | .893 |
| IPI 4-5 | 16 (13) | 23 (18) | .266 | 7 (7) | 32 (23) | .001 |
| CHOP | 42 (34) | 103 (80) | <.001 | — | — | — |
| CHOEP | 82 (66) | 25 (20) | — | — | — | — |
| PTCL NOS | 44 (34) | 65 (52) | — | 41 (38) | 68 (47) | — |
| ALKneg ALCL | 31 (24) | 21 (17) | — | 27 (25) | 25 (17) | — |
| AITL | 27 (21) | 20 (16) | — | 18 (17) | 29 (20) | — |
| EATL | 20 (16) | 14 (11) | — | 17 (16) | 17 (12) | — |
| TCL U | 2 (2) | 8 (6) | — | 4 (4) | 6 (4) | — |
| 5-y OS (%) | 48 | 26 | — | 47 | 30 | — |
| 5-y PFS (%) | 41 | 20 | — | 40 | 23 | — |
Data are presented as n (%) unless otherwise indicated. Dare missing for B symptoms (n = 3), stage (n = 1), WHO PS (n = 3), bulky disease (n = 2), and IPI (n = 9).
BM, bone marrow; LDH, lactate dehydrogenase; ULN, upper limit of normal. CNS, central nervous system; GI, gastrointestinal.
Statistical comparison between stage I-II and stage III-IV.